Picture of Lobe Sciences logo

LOBE Lobe Sciences Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapMomentum Trap

Momentum

Relative Strength (%)
1m-16.67%
3m+21.01%
6m+45.35%
1yr+75.36%
Volume Change (%)
10d/3m-50.1%
Price vs... (%)
52w High-25%
50d MA+5.63%
200d MA+36.36%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Aug 202531st Aug 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Lobe Sciences EPS forecast chart

Profile Summary

Lobe Sciences Ltd. is a Canada-based biopharmaceutical company focused on developing medicines to treat diseases with unmet medical needs. The Company, through collaborations with partners, is engaged in research and development focused on treating chronic cluster headache (an orphan disease), refractive anxiety, and sickle cell disease. In addition, the Company is commercializing Altemia, for the treatment of patients diagnosed with Sickle Cell Disease. The Company is engaged in Phase 1 and Phase 2 activities in its drug portfolios. Its subsidiaries include Eleusian Biosciences Corp., Lobe Sciences Australia Pty Ltd., and Altemia & Company, LLC.

Directors

Last Annual
August 31st, 2024
Last Interim
February 28th, 2025
Incorporated
May 13th, 2010
Public Since
June 19th, 2012
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
ca flag iconCanadian Securities Exchange
Shares in Issue
192,652,124

LOBE Share Price Performance

Upcoming Events for LOBE

Q3 2025 Lobe Sciences Ltd Earnings Release

Similar to LOBE

Picture of 1933 Industries logo

1933 Industries

ca flag iconCanadian Securities Exchange

Picture of 1CM logo

1CM

ca flag iconCanadian Securities Exchange

Picture of Adastra Holdings logo

Adastra Holdings

ca flag iconCanadian Securities Exchange

Picture of Aion Therapeutic logo

Aion Therapeutic

ca flag iconCanadian Securities Exchange

Picture of Asia Green Biotechnology logo

Asia Green Biotechnology

ca flag iconCanadian Securities Exchange

FAQ